Genetics of Hypertension Associated Treatments (GenHAT)

NCT00006294 | Completed

• 2 other identifiers: 911R01HL063082
• Study Type: observational
• Target: 37,939
• Locations: 1 country
• Sites: 1

Brief Summary

To examine whether the association between selected hypertensive genes and combined fatal coronary heart disease and nonfatal myocardial infarction in high-risk hypertensives is modified by the type of antihypertensive treatment, leading to differential risks of coronary heart disease.

Conditions

Cardiovascular Diseases; Heart Diseases; Hypertension; Coronary Disease; Myocardial Infarction

Outcome Measures

Primary Outcomes (1)

• Blood Pressure

  Blood pressure will be measured to determine the effect of the prescribed anti-hypertensive . Data will be presented as the change in blood pressure over the course of six months

  baseline and six month

Secondary Outcomes (1)

• Effect of genotype on event rates

  6 years

Study Arms (4)

Chlorthalidone

Participants will take chlorthalidone at recommended doses to control hypertension

Drug: Chlorthalidone

Amlodipine

Participants will take Amlodipine at recommended doses to control hypertension

Drug: Amlodipine

Lisinopril

Participants will take Lisinopril at recommended doses to control hypertension

Drug: Lisinopril

Doxazosin

Participants will take Doxazosin at recommended doses to control hypertension

Drug: Doxazosin

Interventions

Chlorthalidone DRUG

participant's drug dose will be titrated from 12.5mg to 25mg over the course of the study

Also known as: Hygroton, Thalitone, Chlorthalid

Chlorthalidone

Lisinopril DRUG

participant's drug dose will be titrated from 10mg to 40mg over the course of the study

Also known as: Zestoretic

Lisinopril

Amlodipine DRUG

participant's drug dose will be titrated from 10mg to 40mg over the course of the study

Also known as: Norvasc

Amlodipine

Doxazosin DRUG

participant's drug dose will be titrated from 2mg to 8mg over the course of the study

Also known as: Cardura

Doxazosin

Eligibility Criteria

• Age: 55 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

Hypertensive individuals, multiple races and ethnic groups are represented in this study population

* not taking anti-hypertensive medication * use of anti-hypertensives for less than two months with a baseline blood pressure between 140/90 and 180/110 * use of anti-hypertensives for greater than two months with a blood pressure not greater than 160/100 * at least one additional cardiovascular risk factor such as previous MI, stroke, type 2 diabetes, smoking, left ventricular hypertrophy or dyslipidemia

Contact the study team to discuss eligibility requirements. They can help determine if this study is right for you.

Sponsors & Collaborators

• Donna Arnett, 257-5678: lead
• University of Minnesota: collaborator
• National Heart, Lung, and Blood Institute (NHLBI): collaborator

Study Sites (1)

University of Kentucky

Lexington, Kentucky, 40536, United States

Location

Related Publications (3)

• Arnett DK, Boerwinkle E, Davis BR, Eckfeldt J, Ford CE, Black H. Pharmacogenetic approaches to hypertension therapy: design and rationale for the Genetics of Hypertension Associated Treatment (GenHAT) study. Pharmacogenomics J. 2002;2(5):309-17. doi: 10.1038/sj.tpj.6500113.

  PMID: 12439737 BACKGROUND

• Arnett DK, Davis BR, Ford CE, Boerwinkle E, Leiendecker-Foster C, Miller MB, Black H, Eckfeldt JH. Pharmacogenetic association of the angiotensin-converting enzyme insertion/deletion polymorphism on blood pressure and cardiovascular risk in relation to antihypertensive treatment: the Genetics of Hypertension-Associated Treatment (GenHAT) study. Circulation. 2005 Jun 28;111(25):3374-83. doi: 10.1161/CIRCULATIONAHA.104.504639. Epub 2005 Jun 20.

  PMID: 15967849 BACKGROUND

• Zhang X, Lynch AI, Davis BR, Ford CE, Boerwinkle E, Eckfeldt JH, Leiendecker-Foster C, Arnett DK. Pharmacogenetic association of NOS3 variants with cardiovascular disease in patients with hypertension: the GenHAT study. PLoS One. 2012;7(3):e34217. doi: 10.1371/journal.pone.0034217. Epub 2012 Mar 28.

  PMID: 22470539 DERIVED

MeSH Terms

Conditions

Cardiovascular Diseases; Heart Diseases; Hypertension; Coronary Disease; Myocardial Infarction

Interventions

Chlorthalidone; Lisinopril; hydrochlorothiazide, lisinopril drug combination; Amlodipine; Doxazosin

Condition Hierarchy (Ancestors)

Vascular Diseases; Myocardial Ischemia; Infarction; Ischemia; Pathologic Processes; Pathological Conditions, Signs and Symptoms; Necrosis

Intervention Hierarchy (Ancestors)

Benzenesulfonamides; Sulfonamides; Amides; Organic Chemicals; Benzene Derivatives; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Hydrocarbons; Benzophenones; Phthalimides; Imides; Ketones; Sulfones; Sulfur Compounds; Isoindoles; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Heterocyclic Compounds; Dipeptides; Oligopeptides; Peptides; Amino Acids, Peptides, and Proteins; Dihydropyridines; Pyridines; Heterocyclic Compounds, 1-Ring; Prazosin; Quinazolines

Study Officials

• Donna Arnett

  University of Kentucky

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR INVESTIGATOR
• PI Title: PI

Study Record Dates

• First Submitted: September 25, 2000
• First Posted: September 26, 2000
• Study Start: September 1, 1999
• Primary Completion: August 1, 2005
• Study Completion: August 1, 2005
• Last Updated: April 26, 2024

Record last verified: 2024-04

Locations

US (1)